Radical change in our understanding of personalized medicine, new ...

B?ttinger and his team at the Institut Charles R. Bronfman for personalized medicine to help other medical centers across the country driving during replication of their study. Also, continue to expand the number of donors consented to the Biobank Mount Sinai, in an effort to discover genetic markers of the disease and more connections between population groups identified.To date, genomic studies have overwhelmingly focused on populations of European origin, raising concerns about the applicability of the results to determine the risk of disease and response to treatment for non-Europeans, and in particular, different genetic backgrounds receiving medical care in urban centers.

Based on their results, researchers at the Bronfman Institute are evaluating the potential clinical utility of hundreds of genetic markers for serious diseases such as heart disease, kidney disease, liver disease, and diabetes, and response to different drugs , throughout the Biobank of samples. The goal is to identify genetic markers that may be useful in predicting the risk of disease in local populations with different genetic backgrounds. The project will be completed by all 20,000 samples of banks by the end of 2011.

?We expect the results for the first time, will lead us to select the appropriate genetic markers, and allow us to provide personalized genomic medicine for patients of different communities at Mount Sinai, who are being treated for diabetes and heart, kidney and liver diseases, among other conditions, ?says Dr. B?ttinger.

RADIANT is conducted in approximately 240 centers in the United States, Canada, Western Europe and Eastern Europe, Asia Pacific and Argentina. The study included patients with stage IB-IIIA NSCLC surgically removed tumors that have EGFR-positive, as measured by immunohistochemistry and / or fluorescence in situ hybridization , and who had completed four cycles of standard adjuvant therapy with platinum chemotherapy or chemotherapy have been naive. Patients were randomized 2:1 to receive Tarceva 150 mg or placebo once daily for two years.

?Our data indicate the importance of assessing patient populations at the local level,? said Dr. B?ttinger. ?Now that we are able to determine the genotype distribution of our patients, we can begin to develop tests and treatments tailored to the diverse communities we serve, which enables us to provide highly effective, personalized care.?

Bronfman Institute for Personalized Medicine, patient consent forms that represent the various communities around The Mount Sinai Medical Center, who confidentially provide DNA samples and plasma to help research in genomics and personalized medicine. The researchers used state of the art genomic technology to determine the genetic makeup, or genotype, of nearly 1,000 local Biobank participants identified themselves as European American, African-American or Hispanic.

They found that there was a continuum with the genetic ancestry at the individual level African American and Hispanic patients who receive care at Mount Sinai ? which means large portions of their genome came from African or mixed European descent, respectively ? and with it genetic variants that indicate the risk of developing a disease.

Source: http://www.exercise24.org/?p=428

WWE Sage Stallone Michael Clarke Duncan Mermaid Body Found Celeste Holm Stephen Covey British Open 2012